Text Size

Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study

Ishikawa H., Oka K., Inoue H.


  • 2026
  • Japanese Journal of Ophthalmology
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Clinical development

  • Affiliations

    Orthoptics and Visual Sciences, Kitasato University School of Allied Health Sciences, Kanagawa, Japan; Santen Pharmaceutical Co., Ltd, 4-20 Ofuka-cho, Kita-ku, Osaka, 530-8552, Japan. koji.oka@santen.com; Santen Pharmaceutical Co., Ltd, 4-20 Ofuka-cho, Kita-ku, Osaka, 530-8552, Japan.

Related Publications

The FAST Study: Examining Quality of Vision Outcomes in Dry Eye Disease Patients with Severe Keratitis Treated with the Ciclosporin A Cationic Emulsion

Pisella P.-J., Mourad A., Ismail D., Garrigue J.-S., Cochener B.


Tear Biomarkers of Topical Sirolimus in Meibomian Gland Dysfunction: A Randomized Trial

Zhou L.; Shimizu H.; Togashi Y.; Kirihara T.; Yang Y.; Lam C.T.; Shimada H.; Tong L.


Layer-by-layer tear film measurement in patients with dry eye and meibomian gland dysfunction

Arita R., Takeuchi G., Sasai K., Nakamura M., Akiba M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022